Lv1
34 积分 2023-01-03 加入
Anti-PEG antibodies: Current situation and countermeasures
2天前
已完结
Recent advances in EZH2-based dual inhibitors in the treatment of cancers
9天前
已完结
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
9天前
已完结
In Vitro Nephrotoxicity and Permeation of Vancomycin Hydrochloride Loaded Liposomes
12天前
已完结
Antibody–drug conjugates for cancer
1个月前
已完结
Isomerization of Poly(ethylene glycol): A Strategy for the Evasion of Anti-PEG Antibody Recognition
2个月前
已完结
Site-selective modification of native proteins
2个月前
已完结
PEGylation technology: addressing concerns, moving forward
2个月前
已完结
Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy
2个月前
已完结
Site-selective modification of native proteins
2个月前
已完结
皖公网安备34019202002308
